Leaderboards/Biosimilars and Bioanalytical Methods

Biosimilars and Bioanalytical Methods

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Ingvill Pedersen Sæbø
Oslo University Hospital
2
Marlena Stielow
Nicolaus Copernicus University
3
Derek M. Mason
Institute of Molecular and Clinical Ophthalmology Basel
4
Emily K. Makowski
University of Michigan
5
Gihanna Galindez
Medizinische Hochschule Hannover
6
Wouter Heyndrickx
Janssen (Belgium)
7
Liese Barbier
KU Leuven
8
Ana M B Amorim
Polytechnic Institute of Coimbra
9
Sigrid Deprez
Ghent University Hospital
10
Filip Miljković
AstraZeneca (Sweden)

Rising Stars Papers

1
Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction
Chemical Research in Toxicology|2024
112 cit.
2
Reduction of monoclonal antibody viscosity using interpretable machine learning
mAbs|2024
34 cit.
3
Predicting adaptive immune receptor specificities by machine learning is a data generation problem
Cell Systems|2024
23 cit.
4
Artificial intelligence-open science symbiosis in chemoinformatics
Artificial Intelligence in the Life Sciences|2024
12 cit.
5
Artificial intelligence in rare diseases: toward clinical impact
Trends in Pharmacological Sciences|2025
7 cit.
6
Inference of differential gene regulatory networks using boosted differential trees
Bioinformatics Advances|2024
5 cit.
7
Rational design of synthetic antimicrobial peptides based on the Escherichia coli ShoB toxin
Scientific Reports|2025
4 cit.
8
Identification of Transcriptional Regulators Using a Combined Disease Module Identification and Prize-Collecting Steiner Tree Approach
Network and Systems Medicine|2025
1 cit.
9
Liver transplantation in recipients with a BMI over 40 kg/m2 is not associated with worse short-term and long-term outcomes
HPB|2024
0 cit.
10
Analytical and diagnostic evaluation of the Anvajo fluidlab 2 analyzer: a novel urine particle analyzer for clinical application using digital holographic microscopy?
Clinical Chemistry and Laboratory Medicine (CCLM)|2026
0 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Camilla Zettel
Betanien Hospital
2
Ellen M. McDonagh
Wellcome Sanger Institute
3
Eithne Walsh
Unknown
4
Emily Helgesen
Oslo University Hospital
5
Rohidas Arote
Seoul National University
6
Wei Xu
Nanjing Medical University
7
Amy Marren
Pfizer (United States)
8
Young Hee Rho
Samsung (South Korea)
9
Y Wang
Lawrence Berkeley National Laboratory
10
Deepak Assudani
GlaxoSmithKline (Germany)

Emerging Leaders Papers

1
Biopharmaceutical benchmarks 2022
Nature Biotechnology|2022
505 cit.
2
The next-generation Open Targets Platform: reimagined, redesigned, rebuilt
Nucleic Acids Research|2022
443 cit.
3
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis
Journal of the American Academy of Dermatology|2024
20 cit.
4
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice
Journal of Clinical Oncology|2024
16 cit.
5
Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
Journal of Dermatological Treatment|2024
10 cit.
6
Efficient gene transfection to lung cancer cells via Folate-PEI-Sorbitol gene transporter
PLoS ONE|2022
8 cit.
7
RecN and RecA orchestrate an ordered DNA supercompaction response following ciprofloxacin-induced DNA damage in <i>Escherichia coli</i>
Nucleic Acids Research|2025
7 cit.
8
Rational design of synthetic antimicrobial peptides based on the Escherichia coli ShoB toxin
Scientific Reports|2025
4 cit.
9
Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma
Nature Communications|2025
4 cit.
10
49140 Clinical similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results
Journal of the American Academy of Dermatology|2024
1 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Désirée van der Heijde
Leiden University Medical Center
2
Henry G. Grabowski
University of North Carolina at Chapel Hill
3
Daniel E. Furst
University of California, Los Angeles
4
Janice M. Reichert
Framingham State University
5
Russell Weiner
Mochida Pharmaceutical (Japan)
6
Christophe P. Stove
Ghent University
7
Timothy Simcoe
Boston University
8
John A. Wagner
Biogen (United States)
9
Tore K Kvien
Diakonhjemmet Hospital
10
Brian K. Shoichet
University of California, San Francisco

Current Senior Leaders Papers

1
The price of innovation: new estimates of drug development costs
Journal of Health Economics|2003
4.3k cit.
2
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Journal of Chemical Information and Modeling|2004
4.1k cit.
3
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Annals of the Rheumatic Diseases|2020
2.8k cit.
4
Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking
Journal of Medicinal Chemistry|2012
2.4k cit.
5
Relating protein pharmacology by ligand chemistry
Nature Biotechnology|2007
2.4k cit.
6
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Annals of the Rheumatic Diseases|2022
1.8k cit.
7
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Annals of the Rheumatic Diseases|2013
1.8k cit.
8
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
Annals of the Rheumatic Diseases|2009
1.6k cit.
9
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis
Arthritis Care & Research|2008
1.5k cit.
10
Percept-percept inflation in microorganizational research: An investigation of prevalence and effect.
Journal of Applied Psychology|1994
1.2k cit.

Reagents for Biosimilars and Bioanalytical Methods

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Fitzgerald Industries InternationalEvidence 70

CD20 antibody (FITC)

#61R-CD20bHUFT
View Evidence →
Fitzgerald Industries InternationalEvidence 70

CD20 antibody

#10R-CD20Chu
View Evidence →
Fitzgerald Industries InternationalEvidence 70

CD20 antibody

#10R-CD20aHU
View Evidence →

🌟 All-Time

Most validated

Innovative ResearchEvidence 72

Mouse Anti-Human CD1a Monoclonal Antibody, Alexa Fluor 488 Conjugated, Clone 143

#CD1A20
View Evidence →
RocklandEvidence 68

Anti-KANK2 (RABBIT) Antibody - 600-401-CD3

#600-401-CD3
View Evidence →
Fitzgerald Industries InternationalEvidence 70

CD20 antibody (PE)

#61R-CD20bHUPE
View Evidence →